Trial Search Results
A Pilot Study of 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
The objective of the study is to evaluate 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for biopsy guidance in patients with suspected prostate cancer.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
Andrei Iagaru
Collaborator: General Electric
Stanford Investigator(s):
Intervention(s):
- Drug: 68Ga RM2
- Drug: 68Ga-PSMA-11
- Device: Investigational PET scanner coils and software
Phase:
Phase 2
Eligibility
Inclusion Criteria:
- Suspected prostate cancer
- Planned prostate biopsy
- Able to provide written consent
- Karnofsky performance status of 50 (or ECOG/WHO equivalent)
Exclusion Criteria:
- Patients not capable of getting PET study due to weight, claustrophobia, or inability
to lay still for the duration of the exam
- Metallic implants (contraindicated for MRI)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Brittney Williams
650-736-3688
Not Recruiting